Cargando…

P71. Adoptive transfer of TCR gene-transduced lymphocytes targeting MAGE-A4 for refractory esophageal cancer

Detalles Bibliográficos
Autores principales:	Shiku, H, Ikeda, H, Miyahara, Y, Ishihara, M, Katayama, N, Tomura, D, Nukaya, I, Mineno, J, Takesako, K, Kageyama, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071937/ http://dx.doi.org/10.1186/2051-1426-2-S2-P45

Ejemplares similares

In vivo persistence of adoptively transferred TCR gene-transduced lymphocytes with anti-tumor reactivity in patients with MAGE-A4 expressing esophageal cancer
por: Ikeda, Hiroaki, et al.
Publicado: (2013)

Tumor-specific donor lymphocyte infusion therapy with allogeneic T cells utilizing novel retrovirus vector silencing endogenous TCR expression
por: Ikeda, Hiroaki, et al.
Publicado: (2014)

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022)

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma
por: Ueda, Shugo, et al.
Publicado: (2018)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome
por: Wang, Linan, et al.
Publicado: (2016)

Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination
por: Abiko, Takehiro, et al.
Publicado: (2018)

A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression
por: Okamoto, Sachiko, et al.
Publicado: (2012)

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial
por: Okumura, Satoshi, et al.
Publicado: (2022)

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Expanding the landscape of TCR gene therapy targeting MAGE
por: Mao, Zhiyuan, et al.
Publicado: (2023)

Generation of TCRα-transduced T cells for adoptive transfer therapy of salmonellosis in mice
por: Kalinina, Anastasiia, et al.
Publicado: (2021)

Avidity optimization of a MAGE‐A1‐specific TCR with somatic hypermutation
por: Bassan, David, et al.
Publicado: (2021)

Expression of MAGE‐1 Gene by Esophageal Carcinomas
por: Toh, Yuji, et al.
Publicado: (1995)

Development of adoptive immunotherapy with KK‐LC‐1‐specific TCR‐transduced γδT cells against lung cancer cells
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics
por: Chen, Xiaohua, et al.
Publicado: (2019)

Systemic CD8(+) T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor
por: Ishihara, Mikiya, et al.
Publicado: (2014)

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody
por: Saeed, Mesha, et al.
Publicado: (2016)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Expression of MAGE‐B Genes in Esophageal Squamous Cell Carcinoma
por: Nagashima, Hideki, et al.
Publicado: (2001)

A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy
por: Casey, Nicholas Paul, et al.
Publicado: (2016)

Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury
por: Asai, Hiroaki, et al.
Publicado: (2014)

Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
por: Kim, Sang T., et al.
Publicado: (2021)

Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas
por: Tanaka, H, et al.
Publicado: (2001)

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers
por: Tono, Yasutaka, et al.
Publicado: (2018)

Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity
por: Sakai, Toshiyasu, et al.
Publicado: (2020)

Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy
por: Matsuzaki, Junko, et al.
Publicado: (2015)

Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy
por: Gerry, Andrew, et al.
Publicado: (2015)

Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy
por: Sanderson, Joseph P, et al.
Publicado: (2019)

Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)

In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)

MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer
por: Suzuki, S, et al.
Publicado: (2008)

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
por: Rath, Jan A., et al.
Publicado: (2020)

Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2017)

Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells
por: Mou, D-C, et al.
Publicado: (2002)

High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma
por: Qi, Yu, et al.
Publicado: (2017)

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules
por: Jin, Jianjian, et al.
Publicado: (2018)

TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer
por: Karahan, Zeynep Sena, et al.
Publicado: (2023)

T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope
por: Saeed, Mesha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_55v1i08jg1iedfvt83vkh4vlbd